title: Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma.
abstract: CCND1, FGFR3 and c-MAF mRNA expression of tumor samples from 123 multiple myeloma patients were analyzed by global RQ/RT-PCR. CCND1, FGFR3 and c-MAF were positive in 44 (36%), 28 (23%) and 16 (13%) of patients, respectively. In 7 patients, both FGFR3 and c-MAF were positive. The expression of c-MAF was independent unfavorable prognostic factors for overall survival (OS). Autologous stem cell transplantation improved progression-free survival of CCND1-positive patients. Bortezomib, thalidomide or lenalidomide extended OS of FGFR3 and/or c-MAF-positive patients. Thus, CCND1, FGFR3 and c-MAF mRNA expression can predict survival and is useful for planning stratified treatment strategies for myeloma patients.
authors.affiliation: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya City, Japan. Electronic address: a.inagaki.21@west-med.jp.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Inagaki
authors.forename: Emi
authors.initials: E
authors.lastname: Tajima
authors.forename: Miyuki
authors.initials: M
authors.lastname: Uranishi
authors.forename: Haruhito
authors.initials: H
authors.lastname: Totani
authors.forename: Yu
authors.initials: Y
authors.lastname: Asao
authors.forename: Hiroka
authors.initials: H
authors.lastname: Ogura
authors.forename: Ayako
authors.initials: A
authors.lastname: Masaki
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Yoshida
authors.forename: Fumiko
authors.initials: F
authors.lastname: Mori
authors.forename: Asahi
authors.initials: A
authors.lastname: Ito
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yano
authors.forename: Masaki
authors.initials: M
authors.lastname: Ri
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kayukawa
authors.forename: Takae
authors.initials: T
authors.lastname: Kataoka
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kusumoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Ishida
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Hayami
authors.forename: Ichiro
authors.initials: I
authors.lastname: Hanamura
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Komatsu
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Inagaki
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Matsuda
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Ueda
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Iida
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics*; D016022:Case-Control Studies; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality; D011379:Prognosis; D011519:Proto-Oncogenes / Q000235:genetics*; D060888:Real-Time Polymerase Chain Reaction; D016019:Survival Analysis; D014178:Translocation, Genetic / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor
keywords: C-MAF; CCND1; FGFR3; FISH; Multiple myeloma; PCR; Survival